Targeted paclitaxel delivery to tumors using cleavable peg-conjugated solid lipid nanoparticles

Pharmaceutical Research

Volumn 31, Issue 8, 2014, Pages 2220-2233

  Zheng, Jie ^a   Wan, Yu ^a   Elhissi, Abdelbary ^b   Zhang, Zhirong ^a   Sun, Xun ^a  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

Author keywords

MMP; paclitaxel; PEG; solid lipid nanoparticles; targeted therapy

Indexed keywords

LIPID; MACROGOL DERIVATIVE; NANOPARTICLE; PACLITAXEL; PEPTIDE FRAGMENT;

ANIMAL; C57BL MOUSE; CARCINOMA, LEWIS LUNG; CHEMISTRY; CHO CELL LINE; CRICETULUS; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG SCREENING; GENETICS; MALE; MOUSE; PROCEDURES;

ANIMALS; CARCINOMA, LEWIS LUNG; CHO CELLS; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; LIPIDS; MALE; MICE; MICE, INBRED C57BL; NANOPARTICLES; PACLITAXEL; PEPTIDE FRAGMENTS; POLYETHYLENE GLYCOLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84894626893     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1320-8     Document Type: Article

References (40)

1. Rivkin I, Cohen K, Koffler J, Melikhov D, Peer D, Margalit R. Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. Biomaterials. 2010;31(27):7106-14.
2. Guo W, Johnson JL, Khan S, Ahmad A, Ahmad I. Paclitaxel quantification in mouse plasma and tissues containing liposome-entrapped paclitaxel by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetics study. Anal Biochem. 2005;336(2):213-20.
3. Konno T, Watanabe J, Ishihara K. Enhanced solubility of paclitaxel using water-soluble and biocompatible 2-methacryloyloxyethyl phosphorylcholine polymers. J Biomed Mater Res A. 2003;65(2):209-14.
4. Yoshizawa Y, Kono Y, Ogawara K, Kimura T, Higaki K. PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. Int J Pharm. 2011;412(1-2):132-41.
5. Yang T, Choi MK, Cui FD, Kim JS, Chung SJ, Shim CK, et al. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release. 2007;120(3):169-77.
6. Hu FQ, Ren GF, Yuan H, Du YZ, Zeng S. Shell cross-linked stearic acid grafted chitosan oligosaccharide self-aggregated micelles for controlled release of paclitaxel. Colloids Surf B: Biointerfaces. 2006;50(2):97-103.
7. Rossi J, Giasson S, Khalid MN, Delmas P, Allen C, Leroux JC. Long-circulating poly(ethylene glycol)-coated emulsions to target solid tumors. Eur J Pharm Biopharm. 2007;67(2):329-38.
8. Li R, Eun JS, Lee MK. Pharmacokinetics and biodistribution of paclitaxel loaded in pegylated solid lipid nanoparticles after intravenous administration. Arch Pharm Res. 2011;34(2):331-7.
9. Caruthers SD, Wickline SA, Lanza GM. Nanotechnological applications in medicine. Curr Opin Biotechnol. 2007;18(1):26-30.
10. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev. 2001;47(1):113-31.
11. Mishra S, Webster P, Davis ME. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biol. 2004;83(3):97-111.
12. Xu H, Deng Y, Chen D, Hong W, Lu Y, Dong X. Esterase-catalyzed dePEGylation of pH-sensitive vesicles modified with cleavable PEG-lipid derivatives. J Control Release. 2008;130(3):238-45.
13. Terada T, Iwai M, Kawakami S, Yamashita F, Hashida M. Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting. J Control Release. 2006;111(3):333-42.
14. Kurschat P, Zigrino P, Nischt R, Breitkopf K, Steurer P, Klein CE, et al. Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J Biol Chem. 1999;274(30):21056-62.
15. Mansour AM, Drevs J, Esser N, Hamada FM, Badary OA, Unger C, et al. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res. 2003;63(14):4062-6.
16. Wan Y, Han J, Fan G, Zhang Z, Gong T, Sun X. Enzyme-responsive liposomes modified adenoviral vectors for enhanced tumor cell transduction and reduced immunogenicity. Biomaterials. 2013;34(12):3020-30.
17. Nikanjam M, Gibbs AR, Hunt CA, Budinger TF, Forte TM. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Control Release. 2007;124(3):163-71.
18. Shimada K, Matsuo S, Sadzuka Y, Miyagishima A, Nozawa Y, Hirota S, et al. Determination of incorporated amounts of poly(ethylene glycol)-derivatized lipids in liposomes for the physicochemical characterization of stealth liposomes. Int J Pharm. 2000;203(1-2):255-63.
19. Zeng N, Hu Q, Liu Z, Gao X, Hu R, Song Q, et al. Preparation and characterization of paclitaxel-loaded DSPE-PEG-liquid crystalline nanoparticles (LCNPs) for improved bioavailability. Int J Pharm. 2012;424(1-2):58-66.
20. Elliott P, Hohmann A, Spanos J. Protease expression in the supernatant of Chinese hamster ovary cells grown in serum-free culture. Biotechnol Lett. 2003;25(22):1949-52.
21. Goutayer M, Dufort S, Josserand V, Royere A, Heinrich E, Vinet F, et al. Tumor targeting of functionalized lipid nanoparticles: assessment by in vivo fluorescence imaging. Eur J Pharm Biopharm. 2010;75(2):137-47.
22. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997;89(17):1260-70.
23. Li SD, Huang L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release. 2010;145(3):178-81.
24. Skubitz KM. Phase II, trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Investig. 2003;21(2):167-76.
25. Kirpotin D, Hong K, Mullah N, Papahadjopoulos D, Zalipsky S. Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). FEBS Lett. 1996;388(2-3):115-8.
26. Andreu D, Albericio F, Solé NA, Munson MC, Ferrer M, Barany G. Formation of disulfide bonds in synthetic peptides and proteins. Methods Mol Biol. 1994;35:91-169.
27. Drummond DC, Zignani M, Leroux J. Current status of pH-sensitive liposomes in drug delivery. Prog Lipid Res. 2000;39(5):409-60.
28. Jackson CJ, Arkell J, Nguyen M. Rheumatoid synovial endothelial cells secrete decreased levels of tissue inhibitor of MMP (TIMP1). Ann Rheum Dis. 1998;57(3):158-61.
29. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 1994;370(6484):61-5.
30. Allen C, Dos Santos N, Gallagher R, Chiu GN, Shu Y, Li WM, et al. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep. 2002;22(2):225-50.
31. Fang C, Shi B, Pei YY, Hong MH, Wu J, Chen HZ. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur J Pharm Sci. 2006;27(1):27-36.
32. Kohane DS. Microparticles and nanoparticles for drug delivery. Biotechnol Bioeng. 2007;96(2):203-9.
33. Xiao K, Luo J, Fowler WL, Li Y, Lee JS, Xing L, et al. A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials. 2009;30(30):6006-16.
34. Martins S, Costa-Lima S, Carneiro T, Cordeiro-da-Silva A, Souto EB, Ferreira DC. Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway. Int J Pharm. 2012;430(1-2):216-27.
35. Xu Z, Gu W, Huang J, Sui H, Zhou Z, Yang Y, et al. In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery. Int J Pharm. 2005;288(2):361-8.
36. Chen DB, Yang TZ, Lu WL, Zhang Q. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull. 2001;49(11):1444-7.
37. Li X, Cheng X, Wang Y, Mao L, Wang Y, Huang Q. Preparation of Paclitaxel Nanosuspension and Study of Its Pharmacokinetic and Biodistrabution Behavior in Rats. Chin Pharm J. 2011;9:015.
38. Zhang Z, Lee SH, Gan CW, Feng SS. In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy. Pharm Res. 2008;25(8):1925-35.
39. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12(4):1317-24.
40. Park K. To PEGylate or not to PEGylate, that is not the question. J Control Release. 2010;142(2):147-8.